Consun Pharmaceutical Group (1681) Fair Value & Analysis

Healthcare · HK · Market cap HK$11.0B

A strong business, screening 90% undervalued on our models.

What matters now

• The rarer combination: high quality (78/100) AND below fair value. That earns a closer look rather than a quick verdict.
• The price is below even our cautious bear case (HK$19.74). The market is more pessimistic than our downside scenario.
• A fairly wide model range (HK$19.74 to HK$42.84) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range HK$2.22 – HK$18.82 · fair‑value band HK$19.74 – HK$42.84 · the HK$13.65 price screens below the HK$25.89 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Consun Pharmaceutical Group (1681) currently trades at HK$13.65, while our model-based Fair Value estimate is HK$25.89, implying the stock looks roughly 89.7% undervalued today. The Quality Score stands at 78/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Consun Pharmaceutical Group generated revenue of HK$3.4B at a net margin of 31.6%. Revenue grew 8.8% year over year. It earns a return on equity of 23.6%. The balance sheet holds a net cash position of HK$1.1B. Fundamentals as of Aug 13, 2026

Our scenario range runs from HK$19.74 (bear case) to HK$42.84 (bull case); at HK$13.65, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 28% below its 52-week high and 33% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 90%, 1681 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (HK$31.28) versus Asset-Based (HK$3.62). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical.

Full company description

Consun Pharmaceutical Group Limited, together with its subsidiaries, produces and sells pharmaceutical products in Mainland China. It operates through two segments, Consun Pharmaceutical and Yulin Pharmaceutical. The company offers uremic clearance granules for chronic renal failure; Yishen Huashi particles for proteinuria; TCM to treat diabetic kidney disease; Gadopentetate Dimeglumine injections for nervous centralis, stomach, chest, pelvic cavity, and extremities, as well as for renal function assessment; Iopamidol injections for neuroradiology, angiography, and urography; and ultrasonic microbubble contrast agent products. It also provides Yuanli Kang, an iron-dextrin oral solution; Yibao Yuan, an erythromycin estolate suspension; Yuantong Ning, a cetirizine hydrochloride oral solution; Zhixueling capsules to treat hysteromyoma bleeding, prolonged lochiorrhea, intermenstrual bleeding, bleeding after use of a contraceptive ring, hemorrhoidal bleeding, and epistaxis; Gyn Antidysmenorrheic tablets for irregular menstruation, period during perimenopause, and abdominal pain during menstruation due to hepatic depression and blood deficiency; and Antibacterial Fujie lotion to treat staphylococcus aureus, candida albicans, and escherichia coli in the feminine vaginal. In addition, the company offers bone-setting liquid; Yunxiang analgesic tincture to treat rheumatism, common cold, headache, stomachache, cardiodynia, and pain in the gastral cavity and chilblain; Sanqi Chuangchun capsules for activating blood circulation and dispersing blood stasis; Shiduqing capsules and tablets, and Paeonol ointment for skin disease; hepatobiliary products, such as Jigucao, Compound Jigucao, and Qinggan tablets, as well as Jigucao Ganyan and Wujun Zhidan granules; and gastroenterology medicines, tonics, and other medicines. Consun Pharmaceutical Group Limited was founded in 1997 and is headquartered in Guangzhou, the People's Republic of China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Consun Pharmaceutical Group reported revenue of HK$3.4B in FY2025 versus HK$2.0B in FY2021, a compound +13.7%/yr. Reported net income was HK$1.1B in FY2025, compounding +16.3%/yr from FY2021.

Watch 1681: get an alert when its fair value changes →

Peer Group

Drug Manufacturers - Specialty & Generic · 622 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.